Coronavirus (COVID-19) Collection
Azithromycin use and outcomes in patients with COVID-19: an observational real-world studyCOVID-19, caused by the new SARS-CoV-2, continues to be widespread, with nearly 600 million cases and >6 million deaths worldwide as of August 29, 2022 (World Health Organization, 2022). Most patients with COVID-19 have flu-like syndrome with a variety of mild symptoms including rhinitis, pharyngitis, cough, and fever. However, some patients experience a more life-threatening disease characterized by respiratory failure, a proinflammatory state, and arterial thromboembolism, which may require hospitalization and intensive care unit (ICU) admission (Bonaventura et al.
Characteristics and outcomes of vaccinated and nonvaccinated patients hospitalized in a single Italian hub for COVID-19 during the Delta and Omicron waves in Northern ItalySince the emergence of SARS-CoV-2 pandemic that causes COVID-19, several efforts have been made to contain and prevent the spread of infection and disease. Among the available interventions, population-based vaccination campaigns have been implemented worldwide after the development of highly effective vaccines (Baden et al., 2021; Polack et al., 2020; Sadoff et al., 2021; Voysey et al., 2021). In Italy, the vaccination campaign started on December 27, 2020, and the following vaccines were adopted for immunization: BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), ChAdOx1 (AstraZeneca), and Ad26.COV2.S (Janssen).
Influence of chronic use of corticosteroids and calcineurin inhibitors on COVID-19 clinical outcomes: analysis of a nationwide registrySince the beginning of 2020, the world has faced the coronavirus disease 2019 (COVID-19) pandemic. As of November 11, 2021, more than 250 million people had contracted COVID-19 worldwide, and more than 5 million had died (Dong et al., 2020).
Bacteraemic pneumococcal pneumonia and SARS-CoV-2 pneumonia: differences and similaritiesStreptococcus pneumoniae remains the most common cause of community-acquired pneumonia (Van der Poll and Opal, 2009; Johansson et al., 2010). Among pneumonia pathogens, it is the leading cause of hospitalization and death in adults (Roson et al., 2001; Shariatzadeh et al., 2005). Approximately 15–25% of cases of pneumococcal pneumonia are bacteraemic (Said et al., 2013), and bacteraemic pneumococcal community-acquired pneumonia (B-PCAP) has traditionally been considered an invasive form of infection related to higher inflammatory status, worse in-hospital course and shorter long-term survival (Capelastegui et al., 2014; Ishiguro et al., 2016; Ruiz et al., 2019).
Mast cell activation symptoms are prevalent in Long-COVIDThe COVID-19 pandemic has spread throughout the world, with calamitous outcomes for some of those acutely infected and for those who struggle with Long-COVID (LC), also known as Long-Haul COVID and post-acute sequelae of COVID-19 (Yong, 2021). Several COVID-19 outcome studies have determined that long-standing, often disabling symptoms are common (Davis et al., 2021, FAIR Health White Paper, 2021, Yong, 2021). The largest studies determined that LC symptoms occurred in: 1) 23.2% overall, and in 50% of those who were hospitalized, in 1.9 million Americans; (FAIR Health White Paper, 2021) 2) 44.2% in 1142 Spaniards; (Fernández-de-Las-Peñas et al., 2021) and 3) 47.1% of 2649 Russians (Munblit et al., 2021).
Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort StudyThe novel coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has exerted enormous relentless pressures on the global healthcare systems. As of February 4, 2021, over 102 million people were infected with SARS-CoV-2, and more than 2.2 million have died since the start of the pandemic (WHO, 2020). The true number of cases may even exceed the number of diagnosed cases by more than 10-fold (Havers et al., 2020; Stringhini et al., 2020).